SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-24-058017
Filing Date
2024-05-07
Accepted
2024-05-07 16:16:15
Documents
15
Period of Report
2024-05-07
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2413689d1_8k.htm   iXBRL 8-K 26218
2 EXHIBIT 99.1 tm2413689d1_ex99-1.htm EX-99.1 107312
6 GRAPHIC tm2413689d1_ex99-1img01.jpg GRAPHIC 11218
  Complete submission text file 0001104659-24-058017.txt   337707

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA rigl-20240507.xsd EX-101.SCH 3006
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE rigl-20240507_lab.xml EX-101.LAB 34240
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rigl-20240507_pre.xml EX-101.PRE 22353
18 EXTRACTED XBRL INSTANCE DOCUMENT tm2413689d1_8k_htm.xml XML 3699
Mailing Address 611 GATEWAY BOULEVARD, SUITE 900 SOUTH SAN FRANCISCO CA 94080
Business Address 611 GATEWAY BOULEVARD, SUITE 900 SOUTH SAN FRANCISCO CA 94080 650-624-1100
RIGEL PHARMACEUTICALS INC (Filer) CIK: 0001034842 (see all company filings)

IRS No.: 943248524 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-29889 | Film No.: 24922126
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)